S Wächter1, K Holzer2, J Manoharan2, C Brehm3, I Mintziras2, D K Bartsch2, E Maurer2. 1. Klinik für Viszeral‑, Thorax- und Gefäßchirurgie, Universitätsklinikum Gießen/Marburg GmbH, Standort Marburg, Baldingerstraße, 35043, Marburg, Deutschland. seckhard@med.uni-marburg.de. 2. Klinik für Viszeral‑, Thorax- und Gefäßchirurgie, Universitätsklinikum Gießen/Marburg GmbH, Standort Marburg, Baldingerstraße, 35043, Marburg, Deutschland. 3. Klinik für Pathologie, Universitätsklinikum Gießen/Marburg GmbH, Standort Marburg, Baldingerstraße, 35043, Marburg, Deutschland.
Abstract
BACKGROUND: Radical en bloc resection of the tumor with ipsilateral hemithyroidectomy and central lymphadenectomy (PTX+HTX) is currently the generally recommended treatment strategy for parathyroid carcinoma (PC) in Germany; however, it remains unclear whether the en bloc resection leads to a prognostic benefit compared to parathyroidectomy (PTX) alone, especially considering disease-free and overall survival. OBJECTIVE: This study analyzed the survival of patients with PC after PTX+HTX compared to patients with PTX. METHODS: Patients with PC were identified from a prospective database and retrospectively analyzed regarding clinicopathological features, surgical treatment, disease-free interval and overall survival. RESULTS: Out of 1705 patients who were operated on because of primary hyperparathyroidism (pHPT), 18 (1.1%) had histologically confirmed PC. In nine patients PTX+HTX was initially performed and the other nine patients received only PTX. After PTX, all of the nine patients developed a recurrence after a median of 18 months (range 7-84 months), while only one patient had a recurrence after PTX+HTX. After PTX a median three (range 2-18) reoperations were indicated for relapse but after PTX+HTX only one patient had to undergo two relapse surgeries (p < 0.001). The recurrence-free survival after PTX+HTX was significantly longer than after PTX (143 vs. 18 months, p = 0.01), while the overall survival of both groups after a median follow-up of 107.5 months did not significantly differ. DISCUSSION: If there is any clinical suspicion of PC, an en bloc resection should be performed to prolong recurrence-free survival and avoid reoperations.
BACKGROUND: Radical en bloc resection of the tumor with ipsilateral hemithyroidectomy and central lymphadenectomy (PTX+HTX) is currently the generally recommended treatment strategy for parathyroid carcinoma (PC) in Germany; however, it remains unclear whether the en bloc resection leads to a prognostic benefit compared to parathyroidectomy (PTX) alone, especially considering disease-free and overall survival. OBJECTIVE: This study analyzed the survival of patients with PC after PTX+HTX compared to patients with PTX. METHODS:Patients with PC were identified from a prospective database and retrospectively analyzed regarding clinicopathological features, surgical treatment, disease-free interval and overall survival. RESULTS: Out of 1705 patients who were operated on because of primary hyperparathyroidism (pHPT), 18 (1.1%) had histologically confirmed PC. In nine patientsPTX+HTX was initially performed and the other nine patients received only PTX. After PTX, all of the nine patients developed a recurrence after a median of 18 months (range 7-84 months), while only one patient had a recurrence after PTX+HTX. After PTX a median three (range 2-18) reoperations were indicated for relapse but after PTX+HTX only one patient had to undergo two relapse surgeries (p < 0.001). The recurrence-free survival after PTX+HTX was significantly longer than after PTX (143 vs. 18 months, p = 0.01), while the overall survival of both groups after a median follow-up of 107.5 months did not significantly differ. DISCUSSION: If there is any clinical suspicion of PC, an en bloc resection should be performed to prolong recurrence-free survival and avoid reoperations.
Entities:
Keywords:
Disease-free survival; Parathyroid carcinoma; Prognosis; Radical resection; Surgery
Authors: Elias Karakas; Hans-Helge Müller; Vladimir K Lyadov; Stephanie Luz; Ralph Schneider; Matthias Rothmund; Detlef K Bartsch; Katja Schlosser Journal: World J Surg Date: 2012-11 Impact factor: 3.352
Authors: Klaus-Martin Schulte; Anthony J Gill; Marcin Barczynski; Elias Karakas; Akira Miyauchi; W T Knoefel; Celestino Pio Lombardi; Nadia Talat; Salvador Diaz-Cano; Clive S Grant Journal: Ann Surg Oncol Date: 2012-03-21 Impact factor: 5.344
Authors: Scott M Wilhelm; Tracy S Wang; Daniel T Ruan; James A Lee; Sylvia L Asa; Quan-Yang Duh; Gerard M Doherty; Miguel F Herrera; Janice L Pasieka; Nancy D Perrier; Shonni J Silverberg; Carmen C Solórzano; Cord Sturgeon; Mitchell E Tublin; Robert Udelsman; Sally E Carty Journal: JAMA Surg Date: 2016-10-01 Impact factor: 14.766
Authors: K M Schulte; N Talat; G Galata; J Gilbert; J Miell; L C Hofbauer; A Barthel; S Diaz-Cano; S R Bornstein Journal: Ann Surg Oncol Date: 2014-02-13 Impact factor: 5.344
Authors: Jessica Limberg; Dessislava Stefanova; Timothy M Ullmann; Jessica W Thiesmeyer; Sarina Bains; Toni Beninato; Rasa Zarnegar; Thomas J Fahey; Brendan M Finnerty Journal: Ann Surg Oncol Date: 2020-07-13 Impact factor: 5.344